GRI Bio, Inc. — fact timeline

GRI Bio, Inc. reported three months ended March 31, 2026 results: net income approximately $2.0 million.

“Net loss for the quarter ended March 31, 2026, was approximately $2.0 million, compared to approximately $3.0 million for the same period in 2025.”

GRI Bio, Inc. amended Amendment No. 1 to At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at increase the aggregate offering price of the Shares that the Company may sell in the ATM Offering fr (effective 2026-01-28).

“On January 29, 2026, the Company entered into an Amendment No. 1 to At The Market Offering Agreement (the “Amendment”) with Wainwright, effective as of January 28, 2026, to increase the aggregate offering price of the Shares that the Company may sell in the ATM Offering from $10,000,000 to up to the dollar amount of Shares registered on the prospectus supplement pursuant to which the ATM Offering is being made.”

GRI Bio, Inc.: Filed Certificate of Amendment to effect a 1-for-28 reverse stock split of common stock, effective January 23, 2026 (effective 2026-01-23).

“On January 21, 2026, GRI Bio, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an amendment (the “Certificate of Amendment”) to its amended and restated certificate of incorporation, as amended, to effect a reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1-for-28 (the “Reverse Stock Split”).”

GRI Bio, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“January 15, 2026, GRI Bio, Inc. (the “Company”) was formally notified by the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Staff has determined that the Company has conditionally regained compliance with the equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) which requires that companies listed on the Nasdaq Capital Market with a market value of less than $35 million and annual net income of less than $500,000 maintain stockholders’ equity of at least $2.5 million (the “Stockholders’ Equity Requirement”). As previously reported on the”

GRI Bio, Inc. entered into Engagement Agreement with H.C. Wainwright & Co., LLC valued at Cash fee 7.0% of gross proceeds, management fee 1.0%, non-accountable expense allowance $25,000, leg (effective 2025-12-11).

“Pursuant to an engagement agreement (as amended, the “Engagement Agreement”) with H.C. Wainwright & Co., LLC (the “Placement Agent”), the Company agreed to pay the Placement Agent in connection with the Offering (i) a cash fee equal to 7.0% of the aggregate gross proceeds received in the Offering, (ii) a management fee equal to 1.0% of the aggregate gross proceeds received in the Offering, (iii) a non-accountable expense allowance of $25,000, (iv) reimbursement of up to $100,000 for legal fees and expenses and other out of pocket expenses and (v) up to $15,950 for the clearing expenses.”

GRI Bio, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at Aggregate offering of 2,603,331 shares, 8,063,336 Pre-Funded Warrants, and 10,666,667 Series F Warra (effective 2025-12-11).

“In connection with the Offering, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors. Pursuant to the Purchase Agreement, the Company agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock or file any registration statement or prospectus, or any amendment or supplement thereto for 60 days after the closing date of the Offering, subject to certain exceptions.”

GRI Bio, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 26, 2025, the Company received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Notice”) based on the information provided in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. Nasdaq Listing Rule 5550(b)(1) requires that companies listed on The Nasdaq Capital Market with a market value of listed securities of less than $35,000,000 and a”

GRI Bio, Inc. engaged WithumSmith+Brown, PC as its auditor.

“On April 11, 2025, the Audit Committee appointed Withum as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.”

GRI Bio, Inc. dismissed Sadler Gibb & Associates LLC as its auditor.

“On April 11, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of GRI Bio, Inc. (the “Company”) approved the dismissal of Sadler Gibb & Associates LLC (“Sadler”) as the Company’s independent registered public accounting firm.”

GRI Bio, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“March 10, 2025, GRI Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the bid price deficiency under Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule"), which the Company previously reported on in its Current Reports on Form 8-K filed on September 10, 2024 and Form 8-K/A filed on September 11, 2024, has been cured, and that the Company is now in compliance with the Minimum Bid Price Rule.”

GRI Bio, Inc.: Filed Certificate of Amendment to effect a 1-for-17 reverse stock split (effective 2025-02-21).

“On February 19, 2025, GRI Bio, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an amendment (the “Certificate of Amendment”) to its amended and restated certificate of incorporation, as amended, to effect a reverse stock split of the Company's common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1-for-17 (the “Reverse Stock Split”).”

GRI Bio, Inc. reported first quarter ended March 31, 2024 results: net income Net loss was $1.9 million.

“GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update”

GRI Bio, Inc. reported financial results for fiscal year ended December 31, 2023.

“On April 1, 2024, GRI Bio, Inc. (the Company) issued a press release announcing its financial results for the year ended December 31, 2023, and provided a business update.”

GRI Bio, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at cash fee equal to 7.0% of the gross proceeds (effective 2024-02-01).

“On February 1, 2024, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), pursuant to which A.G.P. agreed to act as exclusive placement agent for the issuance and sale of the Shares and Warrants.”

GRI Bio, Inc. entered into Securities Purchase Agreement with each purchaser identified on the signature pages thereto valued at combined purchase price of $1.10 (effective 2024-02-01).

“On February 1, 2024, GRI Bio, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement with each purchaser identified on the signature pages thereto (the “Purchase Agreement”), pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”), (i) 330,450 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) 4,669,550 pre-funded warrants (the “Pre-Funded Warrants”) exercisable for an aggregate of 4,669,550 shares of Common Stock, (iii) 5,000,000 Series B-1 common warrants (the “Series B-1 Common Warrants”) exercisable for an aggregate of 5,000,000 shares of Common Stock, and (iv) 5,000,000 Series B-2 common warrants (the “Series B-2 Common Warrants,” and together with the Series B-1 Common Warrants, the “Common Warrants”) exercisable for an aggregate of 5,000,000 shares of Common Stock.”

GRI Bio, Inc.: Amended certificate of incorporation to effect a 1-for-7 reverse stock split (effective 2024-01-29).

“On January 29, 2024, GRI Bio, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an amendment (the “Certificate of Amendment”) to its amended and restated certificate of incorporation to effect a reverse stock split of the Company's common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1-for-7 (the “Reverse Stock Split”).”

GRI Bio, Inc. shareholders approved Approval of an amendment to the amended and restated certificate of incorporation to effect a reverse stock split at a ratio within the range of not less than one-for-two and not more than one-for-nine at the 2024-01-19 meeting.

“Proposal 1 The proposal to approve an amendment to the amended and restated certificate of incorporation of the Company to effect a reverse stock split of the Company’s common stock at a ratio within the range of not less than one-for-two and not more than one-for-nine, with the exact ratio to be set within this range by the Company's board of directors (the "Board") in its sole discretion (without reducing the authorized number of shares of Company common stock) and with the Board able to elect to abandon such proposed amendment and not effect the reverse stock split authorized by the Company's stockholders in its sole discretion, was approved by a majority of the votes cast by Company stockholders at the Special Meeting. Votes For Votes Against Votes Abstained Broker Non-Votes 1,158,012 817,185 2,247 0”

GRI Bio, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 22, 2023 from the Staff notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Notice”) based on the information provided in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. Nasdaq Listing Rule 5550(b)(1) requires that companies listed on The Nasdaq Capital Market with a market value of listed securities of less than $35,000,000 and annual net income of less than $500,000 maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equ”

GRI Bio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 5, 2024, GRI Bio, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”), indicating that the Company no longer meets the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) because the closing bid price for the Company’s common stock was less than $1.00 for the previous 30 consecutive business days. The Letter is in addition to the previously disclosed letter received on November 22, 2023 from the Staff notifying the Company tha”

GRI Bio, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 22, 2023, GRI Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Notice”) based on the information provided in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. Nasdaq Listing Rule 5550(b)(1) requires that companies listed on The Nasdaq Capital Market with a market value of listed securities of less than”

GRI Bio, Inc. reported the quarter ended September 30, 2023 results: net income Net loss was $11.0 million for the nine months ended September 30, 2023.

“GRI Bio, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2023, and provided a business update.”

GRI Bio, Inc. entered into Asset Purchase Agreement with Aardvark Therapeutics, Inc. valued at $250,000 upfront cash payment plus potential milestone payments (effective 2023-08-22).

“On August 22, 2023, GRI Bio, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Agreement”) with Aardvark Therapeutics, Inc. (the “Buyer”), pursuant to which the Buyer agreed to purchase (i) the Company’s license agreement with Medice Arzneimittel Pűtter GmbH & Co. KG, dated January 6, 2020, (ii) certain patents related to the Company’s ADAIR product candidate, and (iii) files (of contract manufacturing and FDA correspondence) for a formulation described in IND No. 133072, ADAIR for the Treatment of ADHD and Narcolepsy, filed with the United States FDA.”

GRI Bio, Inc. reported financial results for the quarter ended June 30, 2023.

“On August 14, 2023, GRI Bio, Inc. (the Company) issued a press release announcing its financial results for the quarter ended June 30, 2023, and provided a business update.”

GRI Bio, Inc. shareholders approved Ratification of the appointment of Sadler, Gibb & Associates LLC as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-07-07 meeting.

“Proposal 2 Ratification of the appointment of Sadler, Gibb & Associates LLC as the Company’s independent registered public accounting firm for the year ending December 31, 2023. Votes For Votes Against Votes Abstained 1,169,668 1,957 523”

GRI Bio, Inc. shareholders approved Election of the following nominees as directors of the Company, each to serve as Class III directors until the Company’s 2026 Annual Meeting at the 2023-07-07 meeting.

“Proposal 1 Election of the following nominees as directors of the Company, each to serve as Class III directors until the Company’s 2026 Annual Meeting and until his successor is duly elected and qualified. Votes For Votes Against Votes Abstained Broker Non-Votes W. Marc Hertz, Ph.D. 1,068,309 1,845 335 101,659 David Szekeres 1,068,073 1,926 490 101,659”

GRI Bio, Inc.: Amended the certificate of incorporation to effect a 1-for-30 reverse stock split (effective 2023-04-21).

“On April 21, 2023, prior to the Effective Time, the Company filed the Stock Split Amendment with the Secretary of State of the State of Delaware to effect the Reverse Split.”

GRI Bio, Inc. underwent a change of control involving GRI Operations, Inc. (closed 2023-04-21).

“Merger Sub was merged with and into GRI (the "Merger"), with GRI surviving the Merger as a wholly owned subsidiary of the Company.”

GRI Bio, Inc. engaged Sadler, Gibb & Associates LLC as its auditor.

“engaged Sadler as the independent registered public accounting firm to audit the Company’s financial statements for the fiscal year ending December 31, 2023”

GRI Bio, Inc. dismissed EisnerAmper LLP as its auditor.

“the Audit Committee of the Board approved the dismissal of EisnerAmper LLP (“EisnerAmper”) as the Company’s independent registered public accounting firm”

David Baker resigned as other_named_officer at GRI Bio, Inc..

“In connection with the resignation for David Baker”

Albert Agro was appointed as Chief Medical Officer at GRI Bio, Inc..

“Albert Agro, Ph.D. as the Company's Chief Medical Officer”

Vipin Kumar Chaturvedi was appointed as Chief Scientific Officer at GRI Bio, Inc..

“Vipin Kumar Chaturvedi, Ph.D. as the Company’s Chief Scientific Officer”

Leanne Kelly was appointed as Chief Financial Officer at GRI Bio, Inc..

“Leanne Kelly as the Company’s Chief Financial Officer (principal financial and accounting officer)”

W. Marc Hertz was appointed as Chief Executive Officer at GRI Bio, Inc..

“the Board appointed W. Marc Hertz, Ph.D. as the Company’s Chief Executive Officer (principal executive officer)”

Camilla V. Simpson was appointed as Director at GRI Bio, Inc..

“the Board appointed W. Marc Hertz, Ph.D., David Szekeres, Roelof Rongen and Camilla V. Simpson, M.Sc. to the Board.”

Roelof Rongen was appointed as Director at GRI Bio, Inc..

“the Board appointed W. Marc Hertz, Ph.D., David Szekeres, Roelof Rongen and Camilla V. Simpson, M.Sc. to the Board.”

David Szekeres was appointed as Chairperson of the Board at GRI Bio, Inc..

“Mr. Szekeres was appointed as the Chairperson of the Board.”

David Szekeres was appointed as Director at GRI Bio, Inc..

“the Board appointed W. Marc Hertz, Ph.D., David Szekeres, Roelof Rongen and Camilla V. Simpson, M.Sc. to the Board.”

W. Marc Hertz was appointed as Director at GRI Bio, Inc..

“the Board appointed W. Marc Hertz, Ph.D., David Szekeres, Roelof Rongen and Camilla V. Simpson, M.Sc. to the Board.”

GRI Bio, Inc. shareholders approved Postponement or adjournment of special meeting to solicit additional proxies at the 2023-04-20 meeting.

“Proposal 5 The Company’s stockholders approved a postponement or adjournment of the Company’s virtual special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the proposals set forth above. Votes For Votes Against Votes Abstained Broker Non-Votes 5,961,827 636,420 88,904 2,316,031”

GRI Bio, Inc. shareholders approved Approval of Amended and Restated 2018 Equity Incentive Plan to increase shares to 6,500,000 at the 2023-04-20 meeting.

“Proposal 4 The Company’s stockholders approved the Amended and Restated 2018 Equity Incentive Plan to, among other things, increase the aggregate number of shares of the Company’s common stock available for issuance thereunder to 6,500,000. Votes For Votes Against Votes Abstained Broker Non-Votes 5,744,077 866,498 76,576 2,316,031”

GRI Bio, Inc. shareholders rejected Amendment to certificate of incorporation to limit liability of officers at the 2023-04-20 meeting.

“Proposal 3 The Company’s stockholders did not approve an amendment to the amended and restated certificate of incorporation of the Company to limit the liability of officers of the Company as permitted by recent amendments to Delaware law. Votes For Votes Against Votes Abstained Broker Non-Votes 5,622,534 825,784 238,833 2,316,031”

GRI Bio, Inc. shareholders approved Amendment to certificate of incorporation to effect reverse stock split at ratio between 1:15 and 1:40 at the 2023-04-20 meeting.

“Proposal 2 The Company’s stockholders approved of an amendment to the amended and restated certificate of incorporation of the Company to effect a reverse stock split of the Company’s common stock at a ratio within the range of not less than 1-for-15 and not greater than 1-for-40 (with such ratio to be mutually agreed upon by the Company and the Investor prior to the Effective Time and with all amendments within such range (other than the amendment setting forth the ratio selected) being abandoned by the Vallon Board). Votes For Votes Against Votes Abstained Broker Non-Votes 8,074,479 739,775 188,928 —”

GRI Bio, Inc. shareholders approved Approval of issuance of shares in connection with Merger and change of control at the 2023-04-20 meeting.

“Proposal 1 The Company’s stockholders approved pursuant to Nasdaq Listing Rules 5635(a), 5635(b), and 5635(d): (i) the issuance of shares of the Company’s common stock pursuant to the Merger, the Equity Financing and the Series T Warrant Exercises, which will represent more than 20% of the shares of the Company’s common stock outstanding immediately prior to the Merger, the Equity Financing and the Series T Warrant Exercises and (ii) the change of control resulting from the Merger, the Equity Financing, and the Series T Warrant Exercises. Votes For Votes Against Votes Abstained Broker Non-Votes 6,094,211 458,506 134,434 2,316,031”

GRI Bio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price.

“December 28, 2022, the Company received a letter from Nasdaq informing it that its shares had failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market and, as a result, its shares are subject to delisting. The Company filed an appeal and hearing request with Nasdaq, which had stayed the delisting of its common stock from The Nasdaq Capital Market pending a Panel decision. The hearing before the Panel was held on February 16, 2023. The Panel reached a decision on February 21, 2023, and informed the Company that it was granting the Company’s r”

GRI Bio, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).

“February 28, 2023, Vallon Pharmaceuticals, Inc. (the “Company”) received notice (the “Second Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that, because the Company’s Annual Report on Form 10-K for the period ended December 31, 2022 reported stockholders’ equity of $2,342,000, and as of February 28, 2023 the Company does not meet the alternatives of market value of listed securities or net income from continuing operations, the Company no longer complies with Nasdaq Listing Rule 5550(b). The Second Notice noted that companies listed on The”

GRI Bio, Inc. reported the fiscal year ended December 31, 2022 results: net income $7.0 million.

“Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results PHILADELPHIA, PA, February 24, 2023 – Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today reported its financial results for the fiscal year ended December 31, 2022.”

GRI Bio, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 28, 2022, having not regained compliance with the Bid Price Rule, the Company received a letter from the Staff notifying the Company that, unless the Company timely requests a hearing, the Company’s common stock would be scheduled for delisting from The Nasdaq Capital Market and would be suspended at the opening of business on January 6, 2023. According to the letter from Nasdaq, the Company has not regained compliance with the Bid Price Rule and is not eligible for a second 180 day extension period because the Company does not comply with the minimum $5,000,000 Stockholders’ Equity i”

GRI Bio, Inc. entered into Agreement and Plan of Merger with GRI Bio, Inc. and Vallon Merger Sub, Inc. (effective 2022-12-13).

“On December 13, 2022, Vallon Pharmaceuticals, Inc. (“Vallon”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with GRI Bio, Inc., a Delaware corporation (“GRI”), and Vallon Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Vallon (“Merger Sub”).”

GRI Bio, Inc. reported financial results for the quarter ended September 30, 2022.

“On November 3, 2022, Vallon Pharmaceuticals, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2022”